4 news items
EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner
CRNX
18 Jun 24
of previous award winners, leading CEOs and other business leaders. Candidates were evaluated based on their ability to create long-term value through
Crinetics To Present New Data Results Of The Phase 3 PATHFNDR-2 Trial Showing Increasing Evidence Positioning Once-Daily, Oral Paltusotine As Potential First-Choice Treatment Option for Acromegaly At ENDO 2024
CRNX
3 Jun 24
DiaryLong-Term Data from Open-Label ACROBAT Advance Extension Study Demonstrated Durable Safety, IGF-1, and Symptom Control at Up to 42
Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly
CRNX
3 Jun 24
Long-Term Data from Open-Label ACROBAT Advance Extension Study Demonstrated Durable Safety, IGF-1, and Symptom Control at Up
Crinetics Pharmaceuticals To Present Advancements From Atumelnant And Paltusotine Development Programs At ENDO 2024 June 1-4, 2024
CRNX
8 May 24
will be Presented, in Addition to New Long-Term Safety and Efficacy FindingsSAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE
- Prev
- 1
- Next